Disruptive nanotechnology solution for the treatment of aggressive cancers with a high incidence worldwide through the intracellular release of monoclonal antibodies in tumour and metastatic cells. This spin-off of the University of Santiago de Compostela has emerged from the laboratory of Professor María José Alonso, where the patented MPN Technology™ platform has been developed. MPN Technology enables progress in the use of biological drugs in the personalised treatment of cancer to treat targets that were previously unapproachable pharmacologically.